In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.
To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.
Roche will find out by September 5 whether its shot at a first-line US lung cancer label has hit the mark.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
New data for heart failure pill could clear the way for use in less severely ill patients.
Two weeks ago BAN2401 was hailed as a possible disease-modifying Alzheimer's drug. Full data at the AAIC meeting to will show whether or not this is was all hype.
Amarin's huge cardiovascular outcomes study of Vascepa will read out soon, but an emphatic victory looks unlikely.
To topple the king the new crop of diabetes drugs must show clear cardiovascular benefits.